RNAi screening reveals requirement for host cell
secretory pathway in infection by diverse families
of negative-strand RNA viruses by Panda, Debasis et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Papers in Veterinary and Biomedical Science Veterinary and Biomedical Sciences, Department of 
2011 
RNAi screening reveals requirement for host cell secretory 
pathway in infection by diverse families of negative-strand RNA 
viruses 
Debasis Panda 
University of Nebraska-Lincoln 
Anshuman Das 
University of Nebraska-Lincoln, adas2@unl.edu 
Phat X. Dinh 
University of Nebraska-Lincoln, s-pdinh3@unl.edu 
Sakthivel Subramaniam 
University of Nebraska-Lincoln 
Debasis Nayak 
National Institutes of Health 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/vetscipapers 
 Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cell and Developmental 
Biology Commons, Immunology and Infectious Disease Commons, Medical Sciences Commons, 
Veterinary Microbiology and Immunobiology Commons, and the Veterinary Pathology and Pathobiology 
Commons 
Panda, Debasis; Das, Anshuman; Dinh, Phat X.; Subramaniam, Sakthivel; Nayak, Debasis; Barrows, 
Nicholas J.; Pearson, James L.; Thompson, Jesse; Kelly, David L.; Ladunga, Istvan; and Pattnaik, Asit K., 
"RNAi screening reveals requirement for host cell secretory pathway in infection by diverse families of 
negative-strand RNA viruses" (2011). Papers in Veterinary and Biomedical Science. 132. 
https://digitalcommons.unl.edu/vetscipapers/132 
This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and 
Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
Debasis Panda, Anshuman Das, Phat X. Dinh, Sakthivel Subramaniam, Debasis Nayak, Nicholas J. 
Barrows, James L. Pearson, Jesse Thompson, David L. Kelly, Istvan Ladunga, and Asit K. Pattnaik 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
vetscipapers/132 
RNAi screening reveals requirement for host cell
secretory pathway in infection by diverse families
of negative-strand RNA viruses
Debasis Pandaa,b, Anshuman Dasa,b, Phat X. Dinha,b, Sakthivel Subramaniama,b, Debasis Nayakc, Nicholas J. Barrowsd,
James L. Pearsond, Jesse Thompsonb, David L. Kellye, Istvan Ladungaf, and Asit K. Pattnaika,b,1
aSchool of Veterinary Medicine and Biomedical Sciences and bNebraska Center for Virology, University of Nebraska, Lincoln, NE 68583; cNational Institute of
Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892; dDuke RNAi Screening Facility, Duke University Medical Center,
Durham, NC 27710; eUniversity of Nebraska Medical Center, Omaha, NE 68198; and fDepartment of Statistics, University of Nebraska, Lincoln, NE 68588
Edited by Peter Palese, Mount Sinai School of Medicine, New York, NY, and approved October 17, 2011 (received for review August 19, 2011)
Negative-strand (NS) RNA viruses comprise many pathogens that
cause serious diseases in humans and animals. Despite their clinical
importance, little is known about the host factors required for their
infection. Using vesicular stomatitis virus (VSV), a prototypic NS RNA
virus in the family Rhabdoviridae, we conducted a human genome-
wide siRNA screen and identified 72 host genes required for viral
infection. Many of these identified genes were also required for
infection by two other NS RNA viruses, the lymphocytic choriome-
ningitis virus of the Arenaviridae family and human parainfluenza
virus type 3 of the Paramyxoviridae family. Genes affecting differ-
ent stages of VSV infection, such as entry/uncoating, gene expres-
sion, and assembly/release,were identified.Depletionof the proteins
of the coatomer complex I or its upstream effectors ARF1 or GBF1 led
to detection of reduced levels of VSV RNA. Coatomer complex I was
also required for infection of lymphocytic choriomeningitis virus and
human parainfluenza virus type 3. These results highlight the evolu-
tionarily conserved requirements for gene expression of diverse fam-
ilies of NS RNA viruses and demonstrate the involvement of host cell
secretory pathway in the process.
RNA interference | transcription and replication | host cell factors for
virus infection
Negative-strand (NS) RNA viruses include a large group ofhuman and animal pathogens that cause diseases ranging
from mild flu-like symptoms to fatal hemorrhagic fever. Vesicular
stomatitis virus (VSV), the prototype of the family Rhabdoviridae,
is an enveloped virus with a nonsegmentedNSRNA genome.VSV
infects most vertebrate and many invertebrate cells and has a short
infection cycle. These characteristics have earned appreciation for
VSV as an excellent model for understanding virus entry, genome
uncoating, replication, assembly, and budding processes, as well as
for studying innate and adaptive immune defense mechanisms.
VSV is also used as a viral vaccine vector, as an oncolytic agent,
and for gene therapy (1).
VSV encodes five proteins: the nucleocapsid protein (N), the
phosphoprotein (P), the matrix protein (M), the glycoprotein (G),
and the large polymerase protein (L) (2). The viral RNA exists in
the virion core as N protein-bound nucleocapsid (NC) to which the
viral polymerase is associated. During infection, VSV binds to
susceptible cells, although the receptor(s) mediating virus entry
remains unidentified (3). It enters cells by clathrin-mediated en-
docytosis, requiring endocytic adaptor protein AP-2, actin, and
dynamin (4–6). Once in the cytoplasm, low pH-dependent fusion
of viral envelope with the endosomal membrane leads to the re-
lease of NC in the cytoplasm for transcription and replication to
occur. Progeny NCs are transported toward the cell periphery in a
microtubule-dependent manner (7). Assembly of the viral com-
ponents occurs at the plasma membrane, and nascent virions are
released from the cells.
Viruses use key cellular pathways for their infection and repli-
cation (8, 9). Although much is known about the viral proteins in
the biology of the virus, little is known about the host factors inVSV
and other NS RNA virus infections. Identifying the cellular factors
and studying the mechanisms of their involvement in these viral
infections is important not only for understanding the biology of
these pathogens, but also for development of antiviral therapeutics.
The advent of siRNA technology and the availability of ge-
nome-wide siRNA libraries have been useful in identifying host
factors required for influenza virus, an NS RNA virus, and several
positive-strand RNA viruses, as well as HIV (10–19). The lack of
similar studies with other NS RNA viruses has limited the un-
derstanding of the role of host cell factors in replication of these
viruses. Using VSV, we conducted a genome-wide siRNA screen
to identify mammalian genes required for viral infection. Our
studies revealed requirements for several cellular pathways and
proteins in VSV infection. Many of the factors identified in the
screen for VSV are also required for infection by two other NS
RNA viruses: the human parainfluenza virus type 3 (HPIV3), a
nonsegmented NS RNA virus in the family Paramyxoviridae, and
the lymphocytic choriomeningitis virus (LCMV), a segmented
genomeNSRNA virus in the familyArenaviridae. Interestingly, for
these three viruses representing diverse families of NS RNA
viruses, viral gene expression required the function of the coat-
omer complex I (COPI), a coat protein complex involved in ret-
rograde vesicular transport from the Golgi to the endoplasmic
reticulum (ER) (20). Overall, the studies reveal a critical need for
the cellular secretory pathway in gene expression of disparate
families of NS RNA viruses.
Results
Genome-Wide RNAi Screen for Host Factors in VSV Infection. To
identify host proteins required for VSV infection, a genome-wide
siRNA screen was conducted. Four independent siRNAs, grouped
into a 2 × 2 pool format (Fig. 1A), targeting each of 22,909
mammalian genes, were used. VSV-eGFP, a recombinant virus
encoding enhanced green fluorescent protein (eGFP) (7), was
used to infect HeLa cells. Expression of eGFP in the cells would
indicate virus infection and gene expression. AllStars nontargeting
(NT) siRNA and siRNAs targeting the VSV L and N mRNAs
were used as controls. At 52 h post-siRNA transfection (hpt), cells
were infected with VSV-eGFP (hereafter VSV), and at 18 h
postinfection (hpi), they were fixed, stained for nuclei, and pro-
cessed for automated image analysis. Cell number and percent
infection were obtained for each well. Infection of NT siRNA-
transfected cells was optimized to yield, on average, 60% infection
rate. Under these conditions, the rate of infection of cells
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transfected with L and N siRNAs was reproducibly <1% (Fig. 1 B
and C). Wells with low cell number due to combined effects of
siRNA toxicity and VSV cytopathic effects (SI Experimental Pro-
cedures) were excluded from further analyses. Sum rank analysis
(21) was used, and 233 host genes (P < 0.01) were identified as
required for VSV infection.
We found several expected genes, including those of the ca-
nonical ribosomal proteins, key parts of the cellular translational
machinery. We deleted the ribosomal protein genes and narrowed
down the list to 173 genes (Dataset S1). Because our screen design
used a 2 × 2 siRNA pool format, the 173 genes exhibited the same
phenotype with at least two different siRNAs (at least one from
each pool), a recommended criterion for true hit identification
(22). Thus, the 173 genes identifiedmay represent factors required
for VSV infection. The biological process categories of cellular
genes overrepresented in the list based on the Panther classifica-
tion system (23) include genes involved in metabolic processes,
nucleic acid metabolism, intracellular protein transport, vesicle-
mediated transport, and exocytosis, among others (Fig. 1D).
Pathway analysis revealed that protein functions involved in at
least eight major cellular pathways were significantly enriched and
showed possible interconnections between these pathways for
VSV infection (Fig. S1A). Comparison of the mammalian genes
identified from genome-wide siRNA screens for other RNA
viruses (10–13, 15, 16, 24, 25) with those from the VSV screen
revealed that genes in several major biological functions categories
are shared by RNA viruses (Fig. S1B).
We then conducted a validation screen for the 173 identified
genes using siRNAs from another source, Dharmacon ON-
TARGETplus pool of four siRNAs. The validation screen was
performed in four replicates, and analysis of the results (SI Ex-
perimental Procedures) led to identification of 72 out of the 173
genes as required for VSV infection (Fig. 1F and Dataset S2).
HPIV3 and LCMV Infection Share Many Factors Required for VSV
Infection. To identify genes and pathways used by diverse families
of NS RNA viruses, the involvement of the 72 genes identified for
VSV was examined in HPIV3 and LCMV infection. These viruses
belong to distinct families of NSRNA viruses and have common as
well as unique strategies for entry, uncoating, replication, and virus
assembly. GFPs expressing LCMV and HPIV3 (26, 27) were used,
and the screen was conducted as described for VSV in duplicate.
By using this strategy, 54 and 27 genes were identified as required
for LCMV and HPIV3 infection, respectively, whereas 25 genes
were required for infection by all three viruses (Fig. 1E). The genes
identified for infection by the three viruses along with their known
and putative functions, can be found in Datasets S2 and S3, re-
spectively. The normalized percent infection for the 72 genes
identified as required for VSV are shown in the heat map (Fig. 1F)
and are compared with those found for LCMV and HPIV3.
Identification of Genes Involved in Various Stages of VSV Infection.
The screen used a multicycle VSV infection assay that included all
stages of the virus infection cycle, such as entry and uncoating,
transcription and replication, and assembly and release. Our
screen identified several subunits of vATPase as necessary for
VSV infection (Fig. 1F and Fig. S2), confirming the known role of
vATPase in endocytosis and virus uncoating (28).
The screen identified several solute carriers localized to the
plasmamembrane, including the solute carrier family 46member 1
[SLC46A1; proton-coupled folate transporter (PCFT)]. We ex-
amined the role of SLC46A1 in VSV infection. Results showed
that in siRNA-treated cells infected with VSV or VSVΔG [a virus
that lacks the G gene and cannot produce infectious virus, so the
infection with this virus is limited to single cycle only (29)], VSV
gene expression (levels of M protein) was reduced (Fig. 2A). We
then transfected VSV NC to cells treated with siRNAs for
SLC46A1 to bypass the endosome-mediated entry and uncoating
and examined the effects of depletion of the protein on gene ex-
pression. VSV NCs are not infectious per se when added to cells
but can initiate the viral genome transcription and replication
when delivered into the cytoplasm by transfection. Results show
that virus gene expression from transfected NCs remained un-
affected (Fig. 2A). Multiple siRNAs from two different sources
also led to reduced viral gene expression as well as depletion of the
SLC46A1 protein (Fig. S3A), indicating that the inhibitory effect
is specific. Together, these results suggest that SLC46A1 may be
required for VSV entry and/or uncoating.
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To identify genes involved in virus assembly and release, we
screened the 72 genes using both multicycle (with VSV) and sin-
gle-cycle (with VSVΔG) infection assays. We found that in ADAL
(Adenosine Deaminase Like) siRNA-treated cells infected with
VSV, the percent infection was ~threefold less compared with the
NT siRNA-treated cells, whereas the percent infection of cells
with VSVΔG was similar in both ADAL and NT siRNA-treated
cells (Fig. 2B). We found no differences in the level of viral gene
expression in cells treated with either siRNAs and infected with
either VSVΔG or VSV (Fig. 2C). However, infectious virus pro-
duction was reduced in VSV-infected cells treated separately with
two different sources of ADAL siRNA (Fig. 2D). These results
suggest that ADAL may facilitate VSV assembly and/or release.
Further, we found that methionine adenosyltransferase 2A
(MAT2A) siRNA treatment reduced VSV gene expression sig-
nificantly (Fig. 2E). MAT2A is involved in L-methionine metabo-
lism and catalyzes formation of S-adenosylmethionine (30).MAT2A
siRNA treatment also reduced gene expression in cells infected with
VSVΔG or in cells transfected with NCs (Fig. 2E). Multiple siRNAs
for MAT2A led to depletion of the MAT2A protein and corre-
sponding reduction in VSV gene expression (Fig. 2F). Viral mRNA
and anti-genome levels were reduced in cells treated with MAT2A
siRNA (Fig. S3B). These results indicate that MAT2A may have a
role in viral gene expression.
COPI Is Necessary for VSV Infection at the Level of Viral Gene
Expression. Network analysis revealed vesicle trafficking as one of
the top scoring pathways required for infection. COPI is involved
in retrograde vesicular transport of luminal and membrane pro-
teins from the Golgi to the ER and intra-Golgi transport (20). We
focused on COPI because multiple proteins in this pathway were
identified and siRNAs for COPI subunits (except COPE) exhibi-
ted strong inhibition of VSV infection (Fig. 1F). Fig. 3A shows
inhibition in VSV infection in cells treated with COPZ1 or
COPB1 siRNAs.
Because the early secretory pathway is necessary for VSV G
protein processing (31), it is possible that the COPI depletion
might have affectedG protein processing and, consequently, virion
assembly and release. To determine whether COPI plays any role
in other steps of theVSV infection cycle, we examined the effect of
COPI subunit siRNAs on VSV gene expression at 4 hpi, a time at
which viral gene expression is readily detectable. At this time, VSV
gene expression was inhibited by all COPI siRNAs (except COPE)
(Fig. 3B). Furthermore, VSVΔGvirus infection of cells depleted of
COPZ1 and COPB1 showed a significant reduction of viral gene
expression (Fig. 3C), indicating that COPI plays a role in facilitating
viral entry, uncoating, and/or gene expression. The degree of in-
hibition of VSV gene expression correlated with the level of de-
pletion ofCOPZ1 (Fig. 3D) andCOPB1 (Fig. S4A).Multiple siRNA
for each of the COPI subunits (except COPE) reduced VSV gene
expression (Fig. S4B).We then used 1,3-cyclohexanebismethylamine
(CBM), an inhibitor of COPI function (32, 33), to examine in-
volvement of COPI in VSV gene expression. Treatment of cells with
CBM 1 h before infection reduced VSVM protein levels in a dose-
dependent manner (Fig. 3E) without adversely affecting the cell vi-
ability (Fig. S5). These studies suggest that COPI is necessary for
VSV infection.
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Fig. 2. Identification of genes for VSV entry/uncoating, assembly/budding,
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using ADAL siRNAs, and percent infection was determined. Values are nor-
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Cells transfected with ADAL siRNA were infected with VSV (0.1 MOI) or
VSVΔG (0.2 MOI), and M protein expression was examined at 5 hpi. (D)
Relative VSV yield (mean ± SD) at 14 hpi (0.001 MOI) after ADAL siRNAs from
Dharmacon (ADAL-D) or Qiagen (ADAL-Q) treatment from three experi-
ments. (E) Effect of siRNA for MAT2A on viral gene expression in cells
infected with VSV or VSVΔG or transfected with NCs. Experimental con-
ditions are as in A. (F) Cells were transfected with individual siRNA duplexes
(Dharmacon) for MAT2A and infected with VSV (0.005 MOI) for 12 h. Cell
lysates were examined for levels of M, actin, and MAT2A proteins.
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and at 14 hpi, they were fixed, stained with DAPI, and imaged at 10× magni-
fication. (B) Cells transfected with siRNAs for COPI subunits for 48 h were
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munoblotting for M. (C) Cells transfected with siRNAs for the COPI subunits as
above were infected with VSVΔG virus. At 5 hpi, viral gene expression was
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were infectedwith VSV for 4 h. VSV gene expression (M level) and COPZ1 levels
were assessed by immunoblotting. (E) Cells pretreated with CBM for 1 h were
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Since COPI is involved in endosomal transport (34), it is pos-
sible that the inhibition of VSV gene expression could be due to
disruption of endosomal transport required for VSV entry and
uncoating. However, inhibition of viral gene expressionwas observed
in NC-transfected cells depleted of COPI subunits (Fig. 3F), sug-
gesting that COPI is required for viral gene expression, independent
of entry anduncoating steps.Additionally, we found reduced levels of
mRNA (transcription product) and anti-genome (replication prod-
uct) in COPZ1-depleted cells (Fig. 3G). Furthermore, when cells
were treatedwithCBM1hafterVSVinfection, a time-frame inwhich
themajority of the viruswouldhaveuncoated theirNCs (35), reduced
levels of mRNA and anti-genome were also observed (Fig. 3H),
suggesting that COPI is required for VSV gene expression.
We then examined whether COPI is also required for gene
expression of LCMV and HPIV3. Cells treated with siRNA for
COPI subunits were infected with GFP-encoding LCMV or
HPIV3. The level of GFP protein was examined in cell extracts
collected at the earliest time point when GFP expression was seen
in infected cells (7 hpi for LCMV or 14 hpi for HPIV3) (26).
Depletion of the COPI subunits (except COPE) significantly
inhibited LCMV and HPIV3 gene expression (Fig. 3I), suggesting
that these viruses also require COPI functions.
Viral Gene Expression Requires ARF1 and GBF1, the Upstream Effectors
of COPI. Activation of ADP ribosylation factor 1 (ARF1) is re-
quired for the recruitment of COPI complex onto the Golgi
membranes (36). In ARF1 siRNA-treated cells infected with
VSV, the viral gene expression was reduced by twofold with
concomitant similar reduction in the levels of ARF1 protein (Fig.
4A and Fig. S6A), suggesting that moderate inhibition of viral gene
expression may be due to insufficient depletion of ARF1. In cells
transfected with a plasmid encoding a dominant-negative mutant,
ARF1-T31N (37), viral gene expression was inhibited (Fig. 4B).
ARF1 depletion also inhibited LCMV gene expression but sur-
prisingly had no effect on HPIV3 gene expression (Fig. 4C). It is
possible that moderate level of ARF1 depletion might not have
shown measurable inhibitory effect on HPIV3 gene expression.
The Golgi-associated brefeldin A resistant factor 1 (GBF1) is
the guanine nucleotide exchange factor, which catalyzes GDP–
GTP exchange to activate ARF1 for COPI recruitment onto the
Golgi membranes (38). GBF1 siRNA reduced endogenous
GBF1 protein levels by >90% and led to significant reduction in
VSV M protein (Fig. 4D). Reduction in VSV mRNA and anti-
genome levels was observed after GBF1 depletion (Fig. S6B),
suggesting that VSV gene expression requires GBF1.
We then used inhibitors of GBF1 to probe its requirement in
VSV gene expression. Brefeldin A (BFA) inhibits GBF1, BIG1
(brefeldin-inhibited guanine nucleotide exchange factor 1), and
BIG2, whereas Golgicide A (GCA) and Tyrphostin AG1478 are
specific inhibitors of GBF1 (39, 40). In the presence of these drugs,
VSV gene expression was inhibited (Fig. 4E and F). The drugs had
no significant adverse effects on viability of uninfected cells (Fig.
S5). We then examined VSV gene expression in Madin Darby
canine kidney (MDCK) cells, which contain a natural mutation
(M832L) in GBF1, rendering the cells resistant to BFA, GCA, and
AG1478 (39–41). However, in these cells, BIG1 and BIG2 are
sensitive to BFA (40). In MDCK cells infected with VSV, viral
gene expression was not adversely affected, even at higher con-
centrations of the drugs (Fig. S6C). Studies with VSVΔG virus
infection (Fig. S6D) and NC transfection (Fig. S6E) showed that
GBF1 is required for VSV gene expression. In LCMV and HPIV3
infected cells, viral gene expression was reduced after depletion of
GBF1 (Fig. 4G) and was sensitive toGBF1 inhibitors (Fig. 4H and
I), indicating that GBF1 is also required for these viruses.
Discussion
In the present study, using a genome-wide siRNA screen, we have
identified host cell factors required for VSV infection. Because of
our screen design (2 × 2 pool of siRNA format) and validation
using a different source of siRNAs, the possibility of false positives
in the list is likely to be low, but it may have compromised our
ability to identify additional genes required for VSV infection. An
integrated model (Fig. 5) revealing the host factors required for
VSV infection demonstrates many previously undescribed func-
tions and pathways used not only by VSV but also by other RNA
viruses such as LCMV and HPIV3. This study provides a com-
parative analysis of cellular factors involved in replication of three
disparate NS RNA viruses. Functions such as RNA processing,
vesicular transport, transcription, and translation regulations, among
others, are shared by all three viruses, which would suggest utiliza-
tion of common cellular functions for their replication. It should be
noted that the factors identified for LCMV and HPIV3 are only
a subset of those identified forVSV and do not represent a complete
set of factors required for either LCMV or HPIV3. However, it is
evident that several of the cellular pathways and factors are shared
by all three viruses, illustrating commonalities in the requirements
for replication of these NS RNA viruses.
Although VSV is phylogenetically more closely related to
HPIV3 than LCMV (42), only 27 of the 72 factors identified for
VSV were required for HPIV3, whereas 54 of those were required
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for LCMV.We noted an enrichment of proteins involved inGPCR
signaling, indicating that signaling through some of these GPCR
components may be required for infection. The observations that
SLC46A1 (PCFT) is specifically required in entry/uncoating,
ADAL is required for assembly/budding, and MAT2A is required
for gene expression of VSV are unique findings of this study.
ADAL was recently discovered as a putative plasma membrane
protein closely related to adenosine deaminase with unknown
function. Further studies are required for understanding the mo-
lecular mechanisms of its involvement in VSV infection. Identifi-
cation of MAT2A, in VSV RNA synthesis, suggests its possible
involvement in VSV mRNA cap formation during transcription.
Whether these identified proteins are directly involved in various
steps in VSV infection or whether they mediate their activities
through other cellular interacting partners (Fig. S7) is of interest
for a mechanistic understanding of their role in VSV infection.
The subunits of COPI complex emerged strongly as factors re-
quired for infection by all three viruses. The heptameric COPI
complex associates with the Golgi membranes, resulting in the
budding of COPI-containing vesicles, whose major function is to
mediate transport of cellular proteins and cargo from the Golgi to
the ER as well as the intra-Golgi transport (20). Depletion of
COPI also perturbs the steady-state distribution of the Golgi
enzymes (43) and thus inhibits processing of the VSV G protein
and its transport to the plasma membrane (44, 45). Further, we
have found that depletion of COPZ1 subunit had no adverse effect
on VSV G protein-mediated entry of pseudotyped HIV (Fig. S8),
consistent with recent studies that BFA has no significant effect on
VSV G-mediated entry of retrovirus (46). The following obser-
vations suggest that COPI is involved in VSV gene expression: (i)
VSV gene expression is inhibited in COPI-depleted cells that are
independent of the viral G protein processing, (ii) pharmacologic
inhibitor of COPI inhibits VSV gene expression as well as viral
RNA levels, and (iii) VSV gene expression is reduced in NC
transfected cells that have been depleted of COPI.
Multiple siRNA screens for influenza virus, an NS RNA virus
that replicates in the nucleus, have identified COPI, but not
COPII, as required for infection (11, 12, 24). Although COPI is
required for influenza as well as VSV G-mediated virus entry (12),
our results for VSV are in contrast to these studies. It is possible
that the assay conditions, cell type used, and other unknown fac-
tors may have contributed to these disparate results. In this report
and also in earlier reports (11, 15, 47), the siRNA for COPE did
not inhibit VSV and other virus infections, indicating that this
protein may not have been depleted sufficiently to observe the
effect or that COPEmay be dispensable for COPI function in viral
infection (11, 15, 47). Transfection of siRNAs for COPII subunits
resulted in statistically nonsignificant reduction of VSV infection
(Fig. S9), indicating that COPII may not be required for VSV,
consistent with the result that it was also not identified in the in-
fluenza virus screens (11, 12, 24). Our results point toward a spe-
cific role of COPI in VSV gene expression. The requirement for
ARF1 and GBF1, the upstream activators of COPI assembly in
modulating VSV RNA levels, suggests a role for the host cell se-
cretory pathway in the process. Whether the COPI complex is
directly involved in regulating the viral polymerase functions or
whether it may signal through downstream effectors required for
viral gene expression is of further interest.
The requirement of COPI for genome replication has been well
documented for positive-strand RNA viruses, which replicate in
association with cytoplasmic membranous structures (9, 15, 47).
Viruses such as polio, hepatitis C, and coxsackie modulate the
activities of ARF1, GBF1, and COPI for formation of intracellular
organelles for replication (48, 49). Vaccinia virus, a DNA virus,
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requires COPI for its biogenesis, whereasHIV lacks a requirement
for COPI (33). The studies presented here reveal a requirement
for COPI in gene expression of VSV, and possibly other NS RNA
viruses, suggesting a critical role of this secretory pathway in RNA
virus infection. Most NS RNA viruses including VSV, LCMV, and
HPIV3, replicate in the cytoplasm. The replication organelles, if
any, for the cytoplasmically replicating NS RNA viruses are un-
known. VSV replicates throughout the cytoplasm of infected cells
(7, 50), although studies do not rule out the existence of specific
replication organelles in the cytoplasm. Further biochemical and
ultrastructural studies in cells infected with VSV and other NS
RNA viruses will likely illuminate the nature of the replication
organelles for these viruses.
In conclusion, this study has identified several previously
undescribed candidates and pathways regulating infection of cells
by VSV and two other NS RNA viruses. The requirement for host
cell secretory pathway in infection by VSV, LCMV, and HPIV3
argues for a common mechanism by which this cellular pathway
modulates NS RNA virus replication.
Experimental Procedures
The high-throughput primary siRNA screenwas performed by using the Qiagen
genome-wide siRNA library (Version 1.0). The validation screen was conducted
by using Dharmacon ON-TARGETplus pool of four siRNAs. Details of the screen
design, statistical analysis, hit identification, and other experimental procedures
can be found in SI Experimental Procedures.
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SI Experimental Procedures
Cells, Viruses, Virus Infections, and Virus Yield Determination. HeLa
(ATCC # CCL2), MDCK, and TZM-bl cells were maintained in
DMEM supplemented with 10% FBS and antibiotics. BHK-21
cells were maintained in MEM with 5% FBS. LCMVr3-GFP (1)
and HPIV3-GFP (2) were grown in BHK-21 cells and titrated in
HeLa cells by fluorescent focus forming assay. Clonal stock of
VSV-eGFPwas prepared by growing the virus in BHK-21 cells and
titrating in HeLa cells by plaque assay. VSV-PeGFPΔG virus has
been described (3). VSV yield was determined by plaque assay on
HeLa cells.
Antibodies. Anti-M (23H12) monoclonal antibody was from
Douglas Lyles (Wake Forest University, Winston-Salem, NC).
Anti-actin, anti-eGFP, and anti-Renilla reniformis-GFP (GFPrr)
antibodies were from Santa Cruz; anti-βCOP, anti-ζCOP, anti-
ARF1, and MAT2A antibodies were from Sigma; anti-GBF1 an-
tibody was from BD Science; and anti-SLC46A1 antibody was
from Abcam.
SDS/PAGE, Immunoblotting, and Quantitation. These procedures are
described (3). Quantitation of proteins detected in the blots was
performed by using Versadoc QuantityOne software (BioRad
Laboratories).
NC Preparation and Transfection. VSV-eGFP NCs were prepared,
and transfection was performed by using Lipofectamine 2000 as
described (3).
RNAi Screen. The primary screen was performed at the Duke
University RNAi screening facility by using the Qiagen genomic
siRNA library v 1.0 consisting of four distinct siRNAs (A, B, C, and
D) targeting 22,909 known and putative human genes. The four
siRNAswere grouped into twopools,with eachpool containing two
siRNAs (set AB and set CD). This format resulted in seventy-four
384-well plates per set and a total of 148 plates for the entire screen.
This 2 × 2 pool design allowed each gene to be tested by two in-
dependent siRNA sets. AllStars nontargeting (NT) siRNA (Qia-
gen) was used as a negative control. Also, siRNAs targeting N and
L genes (two per gene) of VSV were synthesized and used as
additional positive control siRNAs. The sequences of the siRNAs
targeting the VSV genes are as follows. N1: 5′-CUGCAAGGC-
CUAAGAGAGA-3′; N2: 5′-UGGAAUACCCGGCAGAUUA-
3′; L1: 5′-GCAGUUAUCCAGCAAUCAU-3′; and L2: 5′-GA-
GAAACGUUGUAGAAUUA-3′.
Corning 384-well tissue culture plates were prearrayed with 1
pmol of siRNAperwell by using theVelocity Bravo liquid handling
system (Agilent Technologies). Each plate was also seeded with
siRNAs targeting VSV N and L gene as well as the NT siRNA.
Lipofectamine RNAiMAX (Invitrogen) was used in the amount of
0.05 μL per well in 10 μL of OptiMEM (Invitrogen). Reverse
transfection of 3,000 HeLa cells was performed with 15.4 nM final
concentration of siRNAs in a 65 μL of total volume. VSV-eGFP
virus (grown in BHK-21 cells and titrated in HeLa cells) was used.
Initial studies of siRNA transfections (48 and 72 hpt), virus in-
fections at different MOIs (0.2, 0.4, 0.5, 0.6, 0.8, 1, 2, and 3 MOI),
and for various lengths of time postinfection (8, 10, 12, 14, 16, and
18 h) were conducted to identify suitable conditions for primary
high-throughput screen. To identify factors involved in all stages of
the VSV life cycle, such as entry and uncoating, replication, and
budding and release, the screen was optimized for MOI and time
to allow multiple rounds of virus infection to occur. As a quality
control metrics for the assay, Z′ factor (4) was calculated between
NT siRNA treated wells and N and L siRNA treated cells. The
multiplicity and time of infection was optimized to obtain a Z′
factor value of>0.5, which would indicate a robust assay. Based on
these initial standardization experiments, the genome-wide screen
was performed by using 0.5 MOI of VSV and 18 h of infection. In
the genomic screen, the Z′ factor between NT and L was calcu-
lated to be 0.44 for AB set and 0.51 for CD set. These Z′ factor
values indicated that we would be able to distinguish the positive
control wells (L and N siRNA treated cells) from control NT
siRNA treated wells in both AB pool and CD pool.
Automated Image Analysis. At the end of the infection, cells were
fixed with 4% paraformaldehyde in PBS, permeabilized with 0.1%
TritonX-100 in PBS, and stained withHoechst 33342 in PBS for 30
min. Stained cells were imaged with a Cellomics ArrayScan VTI
automated microscope. Images were analyzed with vHCS Scan
Target Activation software v 5.1.2 to identify infected cells. Cells
without VSV-eGFP infection served as reference population for
background fluorescence. Four fields per well of a 384-well plate
were imaged at 10× magnification. First, cells were identified by
their nuclei staining in channel 1 of Cellomics. Cells that scored
positive in channel 1 were analyzed for GFP expression in channel
2, and GFP intensity was calculated for the cells. Frequency dis-
tribution of GFP intensity was plotted and compared between NT
siRNA transfected controls infected with VSV-eGFP or un-
infected reference population. For selection of infected cells,
threshold was set by manual inspection of representative images
from VSV-eGFP infected and uninfected cells. Cells appearing at
least 5 SDs away from the average intensity of uninfected control
population in the same plate or same batch were considered
positive for GFP expression. Once the threshold was determined,
all of the plates were subjected to data analysis by vHCS Target
activation software. Finally, data were obtained by using vHCS
View software v 5.1.2, and the numbers of cells present in the well
were identified as “Valid Object Count” (VOC), whereas the
percentage of infection was determined as “% selected.”
Statistical Analysis. Transfection of siRNAs and subsequent in-
fection with VSV resulted in reduced cell number for some wells
due to the combined effects of siRNA toxicity, loss of cell survival
factors, and VSV cytopathogenicity. We used a cutoff value of 800
ormore cell number in four fields per well for further analysis. This
criterionrequires thatwells transfectedwithsiRNAsetsABandCD
for a particular gene should have a VOC of at least 800. Using this
criterion, we discarded ~24% of the genes in the library. Because
our screen was designed to identify factors whose depletion would
reduce VSV infection, the genes discarded from further analysis
due to reduced cell numbers may potentially represent restriction
factors and/or factors required for cell survival. In other words, if
a gene is required for VSV infection, its depletion would reduce
VSV replication and thus would not promote VSV-mediated cell
death. We would then expect to observe higher cell number in
those wells. So, rationally, the remaining 76% of the genes in the
library should include factors required for VSV replication.
In the screen, for both AB set and CD set, we did not observe a
correlation between percent infection and cell number [r (corre-
lation coefficient) = 0.308 (for AB set) and 0.295 (for CD set)]. It
has been reported that cell density may impact clathrin-mediated
endocytosis and may subsequently affect virus infection (5).
However, throughout the primary screen, we used a cell density
(3,000 plated cells per well) and MOI (0.5) as well as time (18 hpi)
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conditions in which the rate of infection remained in the linear
range. The distribution of percent infection for genomic pop-
ulation for the AB and CD pools did not follow a normal distri-
bution, and thus parametric tests would not have given meaningful
results. Therefore, we used a nonparametric analysis, the Sum rank
statistics (6), to identify the hits from the primary screen. Because
of day-to-day variation in percent infection of NT control pop-
ulation, we decided to use batch-wise analysis to get the primary
hits. Percent infection values for set AB and set CD were ranked
independently from lowest to highest and given ranks from 1 to n
(n = the number of samples analyzed), respectively. Sum rank for
a particular gene is the sumof rank inAB set and rank in CD set for
that gene. The P value for each gene was then determined, and
finally samples were aligned according to the P value. A total of 233
genes with P < 0.01 were identified as primary candidate hits.
Validation Screen. The validation screen was conducted at the
Eppley Institute for Cancer Research at the University of
Nebraska Medical College (UNMC) by using Dharmacon ON-
TARGETplus pool of four siRNA. The sequences of Dharmacon
siRNAs did not overlap with those of Qiagen siRNAs, allowing us
to test multiple siRNA. The assay was conducted by using 96-well
plates. Six microliters of pooled siRNA (500 nM) was prearrayed
per well in 96-well plates by using the Biomek FX liquid handling
system. Lipofectamine RNAiMAX and OptiMEM mix was
prepared (0.25 μL of LipofectamineRNAiMAX in 20 μL of
OptiMEM per well). For experiments using VSV, 15,000 cells in
75 μL of DMEM with 10% FBS and 1× PKS per well were added
to each well to yield a final concentration of 30 nM siRNAs. For
LCMV and HPIV infection, 10,000 cells per well were added in
75 μL of above medium. Cells were incubated for 50 h for
knockdown of the genes. For VSV-eGFP infection, 0.05 MOI of
virus was added in 100 μL of DMEM 2% FBS and 1× PKS per
well by using a multichannel pipette. LCMVr3-GFP (0.05 MOI)
and HPIV3-GFP (0.2 MOI) were used to infect HeLa cells.
Virus inoculum containing required MOI of viruses were pre-
pared in 40 μL of DMEM (with 5% FBS and PKS) per well.
After 1 h of infection, 60 μL of DMEM with 5% FBS and 1×
PKS was added to each well. Cells were infected with VSV for
14 h, with LCMV for 36 h, or with HPIV3 for 41 h. Infected cells
were fixed as per the protocol described in the primary screen.
Cells were stained with DAPI to stain the nuclei. Image analysis
was performed in Cellomics ArrayScan VTI at UNMC to obtain
the VOC and percent infection. Experiment was repeated four
times for VSV and two times each for LCMV and HPIV3.
Meaningful between-plate comparisons required normalization
due to variations among plates. Therefore, we normalized the
percent infection values by plate-wise medians, separately for
siRNA-treated and untreated control samples. We applied the
nonparametric Wilcoxon-Mann-Whitney (WMW) rank-sum test
(7). Despite the lower statistical power of the nonparametric
tests compared with the parametric tests, the WMW test in-
dicated significant effects of the siRNA treatment in the majority
of genes compared with untreated controls at the P ≤ 0.01 level.
Normalization was performed by in-house PERL and MATLAB
programs. The WMW tests, heat map representations, and other
graphics were carried out in MATLAB.
siRNA Transfection in 12-Well Plate. Reverse transfection of HeLa
cell was performed in 12-well tissue culture plates. Final con-
centrations of siRNAs were 20 nM, except for COPI where 10 nM
concentrations of siRNAswere used. Required amount of siRNAs
were plated in the wells. Lipofectamine RNAiMAX in OptiMEM
was prepared (2 μL of Lipofectamine in 300 μL of OptiMEM per
well) and added to the wells. Plates were incubated for 30 min
for complex formation. HeLa cells (200,000 cells per well in 500
μL of DMEM 10% FBS+ PKS) were added for COPI experi-
ments. For other siRNA transfection experiments, 100,000 cells
were added. Cells were further incubated for 42–44 h for COPI
siRNAs and 66–68 h for other siRNA transfection. All of the
experiments were conducted with Dharmacon ON-TARGET-
plus siRNAs, except that where indicated, the Qiagen siRNAs
were used.
Quantitative RT-PCR (qRT-PCR). qRT-PCR was used to measure the
VSV P mRNA, genome, and anti-genome levels. Total RNA was
extracted from cells by TRIzol according to manufacturer’s
protocol (Invitrogen). First-strand cDNA was synthesized from
200 ng of total RNA by using M-MLV reverse transcriptase
according to manufacturer’s protocol (Invitrogen). For quanti-
fication of P mRNA and the internal control β-actin mRNA,
oligo-(dT) was used as primer in one RT reaction. For quanti-
fication of anti-genome and the internal control β-actin mRNA,
VSV2955R and β-actin1 R (each 2 pmol) were used as primers
in another RT reaction. These cDNAs were used as templates in
qRT-PCR reactions that were carried out in Cepheid Smart
Cycler. The sequences and optimized concentrations of the pri-
mers and probes are listed in Tables S1 and S2, respectively.
Lightcycler 480 probe master mix (Roche Applied Sciences) was
used in qRT-PCR reactions. The thermal setup conditions used
included initial denaturation at 95 °C for 5 min, denaturation at
95 °C for 30 s, and annealing and extension at 60 °C for 30 s for
a total of 40 cycles. Relative fold change in VSV P mRNA and
anti-genome levels was calculated by ΔΔCt method. Briefly, the
difference in threshold cycle (ΔCt) was calculated by dividing Ct
value of VSV P mRNA or anti-genome with Ct value of the
respective β-actin internal control. The relative fold change in
VSV P mRNA or anti-genome levels was calculated by dividing
the ΔCt value of siRNA treated sample with ΔCt value of NT
siRNA-treated sample.
Semiquantitative RT-PCR. VSV N mRNA and anti-genome levels
were examined as described in our previous publication (3).
Cell ViabilityMeasurement.Cell viability was measured by CellTiter
Glo assay (Promega). Briefly, 30,000 cells were plated per well in a
clear bottom black wall 96-well plate. Cells were treated with the
indicated concentrations of the drugs in 100 μL of volume and
further incubated for the appropriate length of time. One hun-
dred microliters of CellTiter Glo reagent was added to the wells
and incubated at room temperature for 10 min. Readings were
taken by using a luminometer.
HIV Pseudotype Experiment. For this experiment, pHIV NL4-3-
based,GFP-expressing reporter construct (8)was used.Togenerate
virus stock, 293T cells were cotransfected with an envelope (VSV-
G or HIV NL4-3) expressing plasmid, along with an Env-deficient,
pHIV NL4-3. HeLa or TZM-bl cells were reverse transfected with
siRNAs against COPZ1, COPG, or ATP6V0B. For COPZ1 and
COPG transfection, cells were incubated for 28–30 h before in-
fection. For ATP6V0B, cells were incubated for 52 h before in-
fection. The siRNA transfected cells were infected with 1.0 × 105
TCID50 VSV-G pseudotyped (HeLa) or NL4-3 env packaged
(TZM-bl) virus stock, and GFP-positive cells were measured by
flow cytometry (BD FACScan) at 40 hpi. To enhance the infectivity
with the NL4-3 env packaged HIV, TZM-bl cells were exposed to
DEAE dextran (33.3 μg/mL) simultaneously with virus for 3.5 h.
Cells were washed two times with PBS and supplemented with
DMEM plus 10% FBS and incubated for 37 h more.
Protein–Protein Interaction Network. Protein–protein interaction
network data were downloaded from the STRING Database (9)
and manually validated for each interaction. Each network was
represented by using the Cytoscape suite (10) as follows: the focal
protein for each network (COPA,MAT2A, SCL46A1, andADAL)
and their respective subunits were color-coded and aligned hori-
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zontally. Network visualizations were redrawn by centering to these
focal proteins and their subunits and to preserve the topologies of
most other highly interconnected subnetworks to the highest pos-
sible extent.
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Fig. S1. Computational pathway analysis of identified factors. (A) Ingenuity pathway analysis (IPA; Ingenuity Systems) identified 8 top biological functional
annotations associated with the 173 identified candidates. Integration of these functions is presented in the form of relationships as direct (solid lines) and
indirect (discontinuous lines) interactions with arrows indicating the direction of the underlying relationship when appropriate. The nodes with gray back-
ground represent molecules identified in our screen, and those with white background are the molecules forecasted by IPA knowledge base. (B) Biological
processes enriched among the 72 genes identified in the validation screen for VSV were compared with those identified for other viruses (1–8). Hit lists were
accessed from these published articles and subjected to the Panther biological classification analysis. The color intensities represent degree of requirement by
the indicated virus. Red and gray represent high degree of dependency. Blue represents little or no dependency on the indicated pathway or process.
1. König R, et al. (2010) Human host factors required for influenza virus replication. Nature 463:813e817.
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Fig. S2. vATPase is required for VSV infection. (A) Cells were transfected with pool of four siRNAs for indicated vATPase subunits for 72 h and infected with
VSV (MOI = 0.01) for 14 h. Cell extracts were examined for VSV gene expression (viral M protein) by immunoblotting. Actin is shown for loading control. (B)
HeLa cells were transfected with the indicated siRNAs and then infected with VSVΔG virus. M protein expression was examined at 5 hpi. (C) Cells transfected as
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examined by immunoblotting at 6 h after NC transfection.
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Fig. S3. SLC46A1 and MAT2A are required for VSV infection. (A) HeLa cells transfected with individual siRNA duplexes targeting SLC46A1 were subsequently
infected with 0.005 MOI of VSV for 14 h. Cell lysates were collected and the viral M protein, actin, and SLC46A1 were examined by immunoblotting. (B) HeLa
cells were transfected with pool of four siRNAs targeting MAT2A and at 48 hpt were infected with VSV. At 4 hpi, levels of mRNA and antigenomic RNAs were
determined as described (1). Levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was shown as internal control.
1. Dinh PX, Beura LK, Panda D, Das A, Pattnaik AK (2011) Antagonistic effects of cellular poly(C) binding proteins on vesicular stomatitis virus gene expression. J Virol 85:9459e9471.
COPB1
D
x1
D
x2
D
x3
D
x4N
T
M
Actin
COPB1
A
R
el
at
iv
e 
Le
ve
ls
 o
f 
M
 E
xp
re
ss
io
n
1.0
0.6
0.2
1.4
ARCN1 COPB2 COPA COPG
N
T
COPZ1 COPB1 COPE
B
Fig. S4. Effect of depletion of COPI subunits on VSV gene expression. (A) HeLa cells transfected with individual siRNA duplexes targeting COPB1 subunit and
subsequently were infected with VSV (MOI = 0.5) for 4 h. VSV gene expression was assessed by immunoblotting for M. Depletion of COPB1 was examined by
Western blotting. (B) HeLa cells transfected with individual siRNA duplexes (four per gene) targeting each of the seven COPI subunits were infected with VSV
(MOI = 0.5) for 4 h. VSV gene expression was assessed by immunoblotting for M. Relative levels of M (mean ± SD) from three experiments are presented.
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Fig. S5. Cell viability after drug treatment. (A) HeLa cells plated in 96-well plate were treated with Brefeldin A (BFA; 5 μg/mL), Golgicide A (10 μM), or AG-1478
(30 μM) for 6 h or CBM (2 mM) for 4 h. Cell viability was measured by CellTiter-Glo assay. (B) Cells plated as described in A were treated with BFA (200 ng/mL),
Golgicide A (5 μM), or AG-1478 (20 μM) for 14 h. Cell viability was measured as described in A.
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Fig. S6. Disruption of ARF1 and GBF1 functions affects VSV RNA synthesis. (A and B) HeLa cells were treated with pool of four siRNAs for ARF1 (A) or GBF1 (B)
and then infected with VSV. VSV-P mRNA or anti-genome levels were examined by qRT-PCR. Values show mean ± SE of measurement (SEM) of duplicate
reactions from two experiments after normalizing to NT control. (C) MDCK cells infected with 1 MOI of VSV were treated with indicated concentrations of the
drugs at 1 hpi. Cell lysates were prepared at 4 hpi, and M and actin levels were assessed by immunoblotting. Relative levels of M (mean ± SD) compared with
vehicle controls from three experiments are presented. (D and E) HeLa cells depleted of GBF1 protein by pool of four siRNAs were infected with VSVΔG virus (D)
or transfected with NCs (E). M protein expression was examined at 5 hpi (D) or 6 hpt (E).
Fig. S7. Protein-protein interaction networks. The protein–protein interaction network for solute carrier family 46, member 1 protein (SLC46A1; proton-
coupled folate transporter, PCFT) (A), ADAL (B), MAT2A (C), and COPI (D). Edges (interactions) are indicated by red colors. Only the proteins directly interacting
with SLC46A1, ADAL, MAT2A, and COPI and their directly interacting proteins are shown. Interactions and annotations were obtained from the STRING
Database (1) and from GeneCards (2), and network visualizations were created using Cytoscape (3).
1. Szklarczyk D, et al. (2011) The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39(Database issue):D561eD568.
2. Safran M, et al. (2010) GeneCards Version 3: The human gene integrator. Database (Oxford) 2010:baq020.
3. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T (2011) Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27:431e432.
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Fig. S8. Depletion of COPI does not affect VSV-G mediated HIV entry. (A) COPZ1, COPG, or ATP6V0B siRNAs transfected HeLa cells or TZM-bl cells were
infected with VSV-G pseudotyped HIV or NL4-3 env packaged virus, respectively. GFP expressing cells were measured by flow cytometry at 40 hpi. Asterisk
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Fig. S9. Transfection of COPII siRNA does not affect VSV infection. HeLa cells were transfected with siRNAs for SEC13L1 and SEC23A (two of the COPII
subunits) or against COPZ1. At 48 hpt, cells were infected with VSV (MOI = 0.01), and normalized percent infection relative to NT siRNA at 16 hpi was
determined.
Table S1. Primer sequences
Primer Sequence
VSV 2795F GTGACGGACGAATGTCTCATAA
VSV2860R TTTGACTCTCGCCTGATTGTAC
VSV2955R TGATGAATGGATTGGGATAACA
β-Actin-F CAAGTACTCCGTGTGTGGAT
β-Actin-R CATACTCCTGCTTGCTGAT
VSV 2825 probe 6-FAM/CCATCCTGCTCGGCCTGAGATAC/TAMRA
β-Actin probe Cy5/TCGCTGTCCACCTTCCAGCAGAT/BHQ
Table S2. Primer and probe concentrations
Primer Primer concentrations, nM Probe Probe concentrations, nM
VSV P mRNA
VSV 2795-F 500 VSV 2825 200
VSV 2860-R 500
VSV anti-genome
VSV 2795-F 1,000 VSV 2825 200
VSV 2955-R 1,000
β-Actin
β-Actin-F 500 βActin 1,000
β-Actin-R 500
Dataset S1. List of genes identified in the primary screen for VSV
Dataset S1
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Dataset S2. List of genes identified for VSV, VSV/LCMV/HPIV3, VSV/LCMV, or VSV/HPIV3
Dataset S2
Dataset S3. Known and putative biological functions and subcellular localization of genes required for VSV
Dataset S3
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